Caris Assure™ detected clonal hematopoiesis (CH) mutations in ~40% of cases and demonstrated that CH identification and correction is vital for accurate therapy selection for cancer patients IRVING, Texas, Nov. 25, 2024 /PRNewswire/ — Caris Life Sciences® (Caris), a leading…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.